Several other secondary endpoints were measured including circulating breast cancer risk biomarkers, such as insulin-like growth factor (IGF) system and hormone levels; cardiocirculatory biomarkers such as fibrinogen, antithrombin III, C-reactive protein (CRP) and cholesterol; bone metabolism biomarkers, in particular C-telopeptide (CTX) and osteocalcin. The gene discussed is CRP; the disease is breast cancer.